U.S. commercial launch of the IQLIK at-home autoinjector for LEQEMBI Alzheimer’s maintenance dosing. Replaces every-2-week IV infusions for patients past the 18-month induction phase. Watch: weekly TRx, payor coverage, infusion-center vs. home channel mix.
What’s at stake
LEQEMBI (lecanemab) is a humanized monoclonal antibody co-developed by Biogen and Eisai that targets and clears amyloid-beta protofibrils — a soluble, toxic form of amyloid thought to drive early Alzheimer's neurodegeneration. By reducing amyloid burden in the brain, it slows the rate of clinical decline in patients with mild cognitive impairment or mild Alzheimer's dementia. LEQEMBI received full FDA approval in 2023 as the first anti-amyloid therapy to demonstrate statistically significant slowing of functional decline in a Phase 3 trial; it is given by IV infusion every two weeks, with an at-home autoinjector in development for the maintenance phase.
No primer in glossary yet.
This event was extracted from a primary disclosure. The full chain of citations is in the disclosure trail below.
Competitive landscape
| Drug | Company | Modality | Mechanism | Phase | Next catalyst |
|---|---|---|---|---|---|
| ZURZUVAEzuranolone | SAGE | small molecule | positive allosteric modulator of GABA-A | ENROLLMENT · Jun 26 | |
| AUVELITYdextromethorphan-bupropion | AXSM | small molecule | NMDA antagonist + sigma-1 agonist | READOUT · May 26 |
Disclosure trail
- Apr 12, 2026·18d agopinned · highest confidenceHIGH confPREXACTtop claimJUL 252026
“Subcutaneous LEQEMBI maintenance dosing is on track for U.S. commercial launch on July 25, 2026, following recent FDA approval of the IQLIK autoinjector.”
conf 94%via llm